- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07911319
TiUltra Implant Study
Comparison of Early Healing Dynamics Between NobelActive S TiUltra and NobelReplace CC Ti Unite Implants Using Resonance Frequency Analysis: A Prospective Clinical Study
This prospective clinical study will compare early healing and implant stability between two Nobel Biocare dental implant systems, NobelActive S TiUltra and NobelReplace CC TiUnite. Approximately 30 implants will be randomly assigned to one of the two implant groups and followed for 12 weeks after placement. Implant stability will be assessed using resonance frequency analysis at implant placement and at approximately 2, 4, 6, 8, and 12 weeks. Clinical healing, radiographic findings, and other treatment-related outcomes will also be evaluated during the follow-up period.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Hanae Saito
- Telefonnummer: 410-706-3646
- E-post: hsaito@umaryland.edu
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21231
- University of Maryland School of Dentistry
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age ≥18 years
- Male or Female
- Partially edentulous patients
- Healed ridges (≥3 months post-extraction with no history of socket preservation or ridge augmentation)
- Adequate bone volume (no need for major grafting)
- Sites requiring a single unit implant
- Provision of informed consent
Exclusion Criteria:
- Systemic or local disease or condition that would compromise bone metabolism, post-operative healing and/or osseointegration e.g. uncontrolled diabetes with self-reported most recent HbA1C > 8.0 within last six months
- Systemic corticosteroids or any other medication that would influence bone metabolism, post-operative healing, and/or osseointegration
- History of osseous degenerative diseases
- Heavy smoking (>10 cigarettes/day)
- Bisphosphonate/antiresorptive therapy
- uncontrolled periodontal disease
- Irradiated bone
- Previous history of failed implants
- Recently grafted/augmented site (< 1 year)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: TiUnite
|
NobelReplace CC TiUnite dental implant placed according to the manufacturer's recommended surgical protocol. |
|
Eksperimentell: TiUltra
|
NobelActive S TiUltra dental implant placed according to the manufacturer's recommended surgical protocol. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Implant Stability Quotient (ISQ) Measured by Resonance Frequency Analysis (RFA)
Tidsramme: Day 0 (implant placement) and Weeks 2, 4, 6, 8, and 12
|
Implant stability will be assessed using an Osstell device/SmartPeg transducer expressed as Implant Stability Quotient (ISQ) values on a scale of 0 to 100. Longitudinal changes in ISQ will be compared between the TiUnite and S-TiUltra implant groups over the 12-week healing period to evaluate differences in implant stability trajectories. |
Day 0 (implant placement) and Weeks 2, 4, 6, 8, and 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean Implant Insertion Torque (Ncm)
Tidsramme: Day 0 (during implant placement)
|
Insertion torque will be recorded during implant placement and expressed in Newton-centimeters (Ncm). |
Day 0 (during implant placement)
|
|
Change From Baseline in Radiographic Marginal Bone Level (mm)
Tidsramme: Day 0 (baseline) and Weeks 6 and 12
|
Marginal bone levels in millimeters (mm) will be assessed using standardized periapical radiographs obtained at implant placement (baseline) and at 6 and 12 weeks after surgery. |
Day 0 (baseline) and Weeks 6 and 12
|
|
Number of Participants With Implant Failure
Tidsramme: From Day 0 (implant placement) through Week 12
|
Implant-related complications, including implant failure and marginal bone loss, will be assessed during the 12-week follow-up period. |
From Day 0 (implant placement) through Week 12
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- HP-00120517
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .